The concomitantly increased 18F-FDG activity in hematopoietic organs (bone marrow and spleen) implies stimulated myelopoiesis contributing to the propagation of the systemic pro-inflammatory state in RA patients in remission using anti-TNF therapy. Here, TNF is linked to rheumatoid arthritis.